Antimicrobials
Ciprofloxacin

Ciprofloxacin

Restricted

High
Good (70 to 90%)
IV/PO $

General Information

Treatment

  • Pyelonephritis
  • Lower respiratory tract infections
  • Skin and soft tissue infections
  • Bone and joint infections
  • Complicated intra-abdominal infections
  • Salmonellosis
  • Infectious diarrhea
  • Febrile neutropenia
  • Endocarditis

Prophylaxis

  • Postexposure prophylaxis of anthrax
  • Surgical site infection
  • Invasive meningococcal disease
  • Most gram positives
  • Stenotrophomonas
  • Anaerobes

Renal and liver function, CBC periodically

  • Dizziness
  • Insomnia
  • Rash
  • N/V
  • Abdominal pain
  • Tendinopathy and rupture
  • Retinal detachment
  • Peripheral neuropathy
  • QTc prolongation
  • Strong CYP1A2 inhibitor and weak CYP3A4 inhibitor - Multiple interactions possible
  • QTc prolongation - Increased risk with other agents that prolong QTc
  • AVOID concomitant administration with antacids, multivitamin & mineral supplements - Space doses by 2 hours

Prisma Health Inpatient Formulary
Suspension: 250 mg/5 mL

Other Available Outpatient Strengths
Suspension: 500 mg/5 mL

Prisma Health Inpatient Formulary
Tablet: 250 mg, 500 mg, 750 mg

Other Available Outpatient Strengths
Tablet: 100 mg

  • Do not administer suspension through feeding tubes
  • Crush and mix tablet instead

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life:

  • Pediatrics: 4-5 hours

Biliary penetration: Good

CSF penetration: 26%

Lung penetration: Excellent

Urine penetration: Excellent kidney penetration

Route of Elimination:

  • 30% to 70% excreted as unchanged drug in urine via glomerular filtration and active tubular secretion
  • 20% excreted in feces primarily from biliary excretion
  • <1% excreted in bile as unchanged drug

Metabolism: Partially hepatic